在肝硬化中治疗肝脑病的基于托代谢的诊断模型的开发
1Department of Gastroenterology, Hunan Provincial Clinical Research Center for Metabolic Associated Fatty Liver Diseases, Hengyang Medical School, The Affiliated Nanhua Hospital, University of South China, Hengyang, 421002, Hunan, China.
European journal of medical research
|January 20, 2026
概括
改变的酸盐代谢与肝硬化患者的肝脑病变 (HE) 有关. 结合血液氨和血清的诊断模型显示出早期HE检测的希望.
科学领域:
- 生物化学 生物化学
- 代谢学 代谢学 代谢学
- 临床诊断 临床诊断 临床诊断
背景情况:
- 托 (TRP) 代谢变化与肝脏脑病 (HE) 病原发生有关.
- 异常的TRP代谢物可以作为肝硬化 (LC) 中HE严重程度的潜在生物标志物.
研究的目的:
- 通过使用向代谢学,在不同阶段的LC患者中表征血清TRP代谢概况.
- 通过整合临床指标和TRP代谢物,开发一种用于LC患者早期HE检测的诊断模型.
主要方法:
- 向液体染色体质谱法 (LC-MS) 用于量化90名LC患者和50名健康对照的血清TRP代谢物.
- 开发了一种后勤回归模型,将差异代谢物与临床指标 (如血氨和血清素 (SER)) 整合在一起.
- 使用AUC,引导验证,校准曲线和决策曲线分析 (DCA) 评估诊断准确性.
主要成果:
- 与对照组相比,LC患者显示出显著的TRP代谢物变化,TRP和SER降低,氨酸和醇衍生物的含量增加.
- 与非HE LC患者相比,HE患者的血清激素 (SER) 水平显著降低.
- 综合血氨和SER的诊断模型表现出强大的区分性能 (AUC=0.902,灵敏度=76.9%,特异性=88.0%) 和临床实用性.
结论:
- 向的TRP代谢组可以在肝硬化患者中区分疾病阶段.
- 结合血氨和SER的诊断模型为LC患者的早期HE检测和监测提供了可靠的方法.
相关概念视频
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
186
In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...
186
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment
260
Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
260
Hepatic Portal System
5.5K
The hepatic portal system, a critical part of our circulatory framework, transports nutrient-laden, deoxygenated blood from the gastrointestinal tract and spleen to the liver. This ingenious system plays an indispensable role in maintaining our body's metabolic equilibrium.
At its core, the hepatic portal vein is the result of a confluence of the superior and inferior mesenteric veins along with the splenic vein. Each of these veins has a unique role. The superior mesenteric vein is...
At its core, the hepatic portal vein is the result of a confluence of the superior and inferior mesenteric veins along with the splenic vein. Each of these veins has a unique role. The superior mesenteric vein is...
5.5K
Physiological Pharmacokinetic Models: Incorporating Hepatic Transporter-Mediated Clearance
280
Drug transporters are critical in drug absorption, distribution, and excretion processes. They should be included in physiological-based pharmacokinetic (PBPK) models, which help predict human drug disposition. However, predicting this is challenging during drug development, especially when liver transport is involved. However, with a realistic representation of body transport processes, an accurate model may be possible.
A recent model describes pravastatin's hepatobiliary excretion,...
A recent model describes pravastatin's hepatobiliary excretion,...
280
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
219
Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...
219
Asthma-IV: Diagnostic and Management
3.1K
The diagnosis and management of asthma are comprehensive, encompassing clinical assessments, lung function tests, and pharmacological interventions. Here's an overview:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
3.1K


